Showing 2601-2610 of 4166 results for "".
- New Study Finds Higher Prevalence of Glaucoma and Related Vision Loss than Previously Estimatedhttps://modernod.com/news/new-study-finds-higher-prevalence-of-glaucoma-and-related-vision-loss-than-previously-estimated/2482513/A
- New Spiral-Shaped Lens Designed to Improve Vision at Range of Distances and Lighting Conditionshttps://modernod.com/news/new-spiral-shaped-lens-designed-to-improve-vision-at-a-range-of-distances/2482108/French researchers have developed a spiral-shaped lens that is designed to maintain clear focus at different distances in varying light conditions. Published in the journal Optica,1 the researchers say the lens works much like progressive lenses used f
- New Long-Term Data for Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)https://modernod.com/news/new-long-term-data-for-genentechs-vabysmo-show-sustained-retinal-drying-and-vision-improvements-in-retinal-vein-occlusion-rvo/2482090/Genentech announced new 72-week data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). The data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48
- Annexon Outlines Registrational Program For ANX007 in GA with FDA Alignment On Vision Preservation As Primary Endpointhttps://modernod.com/news/annexon-outlines-registrational-program-for-anx007-in-ga-with-fda-alignment-on-vision-preservation-as-primary-endpoint/2482025/Annexon outlined its global registrational program for ANX007, a first-in-class C1q and classical complement inhibitor, for the treatment of patients with geographic atrophy (GA). Annexon has gained alignment with the FDA on a phase 3 registration program that includes using,
- Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to 4 Months for People with RVO in Phase 3 Trialshttps://modernod.com/news/genentechs-vabysmo-maintained-vision-improvements-with-extended-treatment-intervals-up-to-4-months-for-people-with-rvo-in-phase-3-trials/2481878/Genentech announced positive topline long-term results from the global phase 3 BALATON and COMINO studies evaluating extended treatment intervals with Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). From weeks 24 to 7
- Prevent Blindness Names Ed Buffington, GPN Technologies, as the 2024 Person of Vision Award Recipienthttps://modernod.com/news/prevent-blindness-names-ed-buffington-gpn-technologies-as-the-2024-person-of-vision-award-recipient/2481856/Prevent Blindness announced that the
- Tenpoint Therapeutics Launches with Goal of Reversing Vision Loss Through Engineered Cell-Based Therapeuticshttps://modernod.com/news/tenpoint-therapeutics-launches-with-goal-of-reversing-vision-loss-through-engineered-cell-based-therapeutics-and-in-vivo-reprogramming/2481720/Tenpoint Therapeutics announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions. Tenpoint was established based on the work of its scientific founders from Mo
- Bausch + Lomb Acquires Blink OTC Eye Drops from J&J Visionhttps://modernod.com/news/bausch-lomb-acquires-blink-eye-drops-from-jj-vision/2481709/The latest in a string of major moves by Bausch + Lomb, the company announced it is purchasing the Blink product line of eye and contact lens
- Lumata Health and Prevent Blindness Announce Partnership Aimed at Delivering More Resources to Americans with Vision Losshttps://modernod.com/news/lumata-health-and-prevent-blindness-announce-partnership-aimed-at-delivering-more-resources-to-americans-with-vision-loss/2481522/Lumata Health announced a partnership with Prevent Blindness which will focus on various initiatives to address barriers to care for patients, with a strong focus on mental health resources to start. “Our care coordinators are in frequent contact with pati
- New Phase 3 Data Show Genentech’s Vabysmo Improved Vision and Reduced Retinal Fluid in People with RVOhttps://modernod.com/news/new-phase-3-data-show-genentechs-vabysmo-improved-vision-and-reduced-retinal-fluid-in-people-with-rvo/2481401/Genentech announced positive new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) at 24 weeks. The studies showed that treatment with Vabysmo resulted in